Recently, Alexander's team identified a novel SHP2 inhibitor, GDC-1971, which exhibited significant antitumor ability in a mouse xenograft model of NSCLC and exerted a synergistic antitumor effect when combined with KRAS inhibitors 137. Here, KRAS is linked to non-small cell lung carcinoma.